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1. Introduction 
1.1 Morphological and functional changes of the small intestine in patients with 
different classes of chronic heart failure 
Current understanding prompts to view chronic heart failure (CHF) as a systemic condition. 
Traditionally, the following organs are considered the target organs of CHF: heart, kidneys, 
brain. However, low cardiac output and increased activity of the renin-angiotensin-
aldosterone system (RAAS), which lead to vasospasm and ischemia, are bound to have 
effect on functions of other organs, including small intestine, large intestine, and adipose 
tissue. The increased activity of RAAS is likely to have effect on morphological restructuring 
of the intestine as well. It can be assumed that accumulation of collagen in the intestinal 
wall, as well as development of edema and ischemia, decrease the functional activity of the 
intestinal wall and are a major factor of the malabsorption syndrome, which, in its turn, 
leads to progressive loss of body mass. This results in progression of certain clinical 
manifestations in patients with CHF, such as: weakness, fatigue, and progressive decrease of 
exercise tolerance, which cannot be explained by changes in peripheral circulation alone. 
The incidence of these complaints is known to increase as the NYHA class of the CHF 
grows, and it reaches its peak in patients with class IV (Harrington & Anker, 1997). 
Loss of body mass means a significantly worse prognosis for the patients with CHF. 
According to SOLVD study, ≥6 % decrease of body mass in patients with CHF is a potent 
predictor of negative impact on survival along with other factors such as age, gender, LV 
ejection fraction, NYHA class (Anker et al., 2003).  
Therefore, decrease of body mass should be considered an important sign, equal in 
significance to such symptoms as dyspnea and edema. 
Obviously, a search for new methods to correct the nutritional status in patients with CHF is 
necessary. The method of nutritional support may be one of these promising options to treat 
and stop development the malabsorption syndrome, as this method constitutes a system 
with pathogenesis-based rationale that implies prescription of balanced nutritive mixtures 
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characterized by maximum degree of absorption even in the setting of morphological 
changes in the intestine.  
1.2 Materials and methods 
This was an open-label prospective study approved by the Ethics Committee of the Russian 
State Medical University. All of the patients participating in this study had signed the 
informed consent. 
The study included 110 patients with New York Heart Association (NYHA) class I-IV 
ischemic CHF, with history of CHF for more than 24 months. Age of the patients was 45 to 
65 years, mean age was 58.7±5.3 years. All of the patients were allocated to different groups 
based on the severity of their CHF. The control group included 38 patients (24 male and 14 
female), 45 to 65 years old (mean age 60.6±2.6), in which no signs of CHF were found after 
testing. The patient populations had comparable basic parameters at baseline.  
All of the patients with the signs of CHF received standard basic therapy, which included 
ACE inhibitors, ǃ-blockers, loop diuretics or thiazide diuretics, cardiac glycosides, nitrates, 
aspirin, and aldosterone antagonists. Patients in the control group received therapy for their 
main condition. 
Patients were investigated using the following sets of tests: 
- Endoscopy with biopsy of the small intestine (the samples were taken 10 cm below the 
plica duodenojejunalis). Preparation and analysis of microscopic specimens were 
performed in the Pathology Department of the Bakulev Scientific Center of 
Cardiovascular Surgery. 
- Assessment of functional activity of the small intestine (measurement of excretion of fat 
in feces, biochemical measurement of total protein and protein fractions in feces via 
nitrogen content, measurement of carbohydrate absorption in the small intestine using 
the D-xylose test).  
Statistical analyses of the results were performed using standard statistical formulas with 
Microsoft Excel 7.0 and BIOSTAT software. Arithmetic means of values in the sample 
population (M) and standard deviations (σ) were determined. The significance of differences 
between groups was determined using Student test at p < 0.05. Relationship between 
parameters was assessed by calculating the correlation coefficient (r) with the level of 
errorless prognosis at 95 % (p<0.05). 
1.3 Results 
1.3.1 Morphological changes of the small intestine in patients with NYHA class I-IV 
CHF 
The photographs of microscopic specimens (Fig. 1) demonstrate the pattern of the mucosa of 
the small intestine typical for patients with NYHA class IV CHF (a) and healthy individuals 
(b). Collagen fibers are stained pink. 
These photographs demonstrate that in patients with NYHA class III-IV CHF the collagen 
fibers stained pink take up a significant area of the small intestine mucosa, while in patients 
without signs of CHF only solitary collagen fibers are present.  
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Fig. 1. The microscopic sample of the mucosa of the small intestine from a patient with 
NYHA class IV CHF (a) and a patient without signs of CHF (b). Van Gieson’s stain, 
magnification х 400.  
a 
b 
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Collagen deposition level in patients with NYHA classes III and IV was significantly different 
from values measured in patients with NYHA classes I or II and in patients without signs of 
CHF. Comparison of collagen relative density between patients without CHF and with NYHA 
class I or II CHF did not reveal significant differences. However, a clear trend towards increase 
of collagen level in the latter was noted. Also, the difference in the amount of collagen between 
CHF patients with NYHA classes III and IV was not significant.  
When assessing the microscopic specimens of the small intestine, high amount of collagen 
was observed to mechanically push enterocytes away from a capillary vessel. This increases 
the intestine-blood barrier and may have an impact on nutrient absorption.  
The measured data are presented in Table 1. 
Groups 
Distance between 
EBM and 
a capillary vessel, 
µm 
Significance of difference between groups 
1. No CHF 8.4±0.7 p1-2 >0.05; p1-3>0.05; p1-4<0.05; p1-5<0.05 
2. NYHA class I 10.1±1.2 p2-3>0.05; p2-4>0.05; p2-5>0.05 
3. NYHA class II 11.3±1.1 p3-4<0.05; p3-5<0.05
4. NYHA class III 18.6±1.4 p4-5>0.05
5. NYHA class IV 19.1±1.2
Table 1. Distance between EBM (enterocyte basal membrane) and the capillary wall 
Even primary assessment of microscopic photographs revealed atrophy of villi of the small 
intestine mucosa in patients with NYHA class III-IV CHF. Fig. 2 shows pattern of the mucosa 
in a patient with NYHA class IV CHF (a) compared to a patient from the control group (b). 
 
a 
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Fig. 2. Villi of the small intestine mucosa in a patient with NYHA class IV CHF (a) and a 
patient without CHF (b).Magnification x100. Hematoxylin-eosin stain. 
Quantitative values describing changes in the villi of the small intestine in patients with 
different classes of CHF are shown in the Table 2. 
Groups 
Mean length 
of a villus, µm 
Mean width 
of a villus, µm 
Significance of difference between 
groups 
No CHF 372±9.9 98±4.4 
p1-2>0.05; p1-3>0.05; p1-4<0.05; 
p1-5<0.05 
Class I CHF 369±7.4 94±3.5 p2-3>0.05; p2-4>0.05; p2-5>0.05 
Class II CHF 374±6.9 91±6.1 p3-4<0.05; p3-5<0.05 
Class III CHF 254±5.5 65±3.1 p4-5>0.05 
Class IV CHF 223±6.1 59±3.0  
Table 2. Length and width of mucosal villi in the small intestine of patients with CHF. 
To conclude, analysis of the small intestine mucosa biopsy samples demonstrated significant 
morphological changes, which worsen with the severity of CHF. Increase of intestine-blood 
barrier and decrease of the absorbing area of the villi determined further study of nutrient 
absorption, which, supposedly, should have decreased significantly in patients with CHF. 
1.3.2 Functional changes of the small intestine in patients with NYHA class I-IV CHF 
Analysis of protein absorption parameters revealed the following pattern: in patients with 
NYHA class I CHF, losses of total nitrogen were virtually below the upper limit of normal 
range, reaching 7.1±0.2 % of daily consumption. No significant differences were found 
b 
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between the patients of the control group (5.9±0.21 %) and classes I or II (p>0.05). With 
NYHA class IV CHF, the loss of protein was significantly higher – 18.6±1.3 %; this was on 
average 3.1 times higher than in the group of patients without CHF (p<0.05). In the group of 
patients with NYHA class III, the loss of protein was 16.7±1.8 %. Comparison of the protein 
loss levels in CHF patients with NYHA class III and IV vs. the protein loss levels in patients 
with NYHA class I and II showed a significant difference (p>0.05).  
Levels of total fat loss were most pronounced in CHF patients with NYHA class III and IV 
(22.4±2.1 % and 24.1±2.12 % of the daily consumption, respectively) and exceeded the levels 
in patients without CHF (5.5±0.86 %) 4-fold on average. For NYHA classes I and II, fat loss 
levels were at the upper limit of normal (6.1±1.1 and 7.2±0.9 % of daily consumption, 
respectively) and were not significantly different from the values in the group of patients 
without CHF (p>0.05).  
Analysis of D-xylose test results demonstrated a dependency similar to the one observed for 
absorption of proteins and fats. In patients with NYHA class IV CHF, the 5-hour excretion of 
D-xylose was 0.89±0.05 g. This was 1.4 times lower than the values for the control group. For 
NYHA class III CHF, D-xylose excretion was 0.96±0.03 g. This was also significantly 
different from normal values. Patients with NYHA class I and II did not show significant 
differences compared to the control group. 
To conclude, patients with CHF experience deterioration of absorption for all basic 
nutrients, and the absorption reduction demonstrates dependence upon the severity of the 
CHF. 
1.4 Attempts for correction 
Taking into consideration the pronounced changes of the small intestine in patients with 
severe CHF that lead to development of malabsorption syndrome and protein-energy 
insufficiency, such patients demand specific correction of their nutritional status. Naturally, 
raw nutrients will hardly be utilized in the intestine that underwent these changes. A 
possibility to use specifically treated nutrients in the form of standard mixes for oral feeding 
was the objective that we assessed in the second phase of this study.  
This part was an open-label, randomized, prospective, 24-week study. 
Patients with NYHA class III and IV CHF were screened for this study. Total number of 
subjects was 74 (46 males, 28 females).  
Randomization was performed using a random number method, with even numbers 
corresponding to the standard-of-care group (Group 1), and odd numbers corresponding to 
the nutritional support group (Group 2). The number of patients assigned to Group 1 was 
36. Group 2 included 38 patients.  
Figure 3 shows the study design. 
Subjects in Group 1 (n=36) received standard basic therapy and their usual nutrition within 
the standard diet for cardiovascular patients. 
Subjects in Group 2 (n=38), in addition to the basic therapy and standard diet, received a 
balanced nutritive mix, comprising 25 % of daily calories. 
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Fig. 3. Study Design. 
The absolute majority of the patients were male and had history of ischemic origin of their 
disease. Their mean age was over 60 years. Mean NYHA class within these groups was 3.5 
and 3.4, respectively. The resulting groups were identical in structure by gender, age and 
other clinical characteristics, warranting their comparability. The following tests were 
performed during this study: 6-minute test, echocardiography (LVEF), diet review, 
measurement of body mass and BMI, estimation of body fat mass and lean body mass, total 
protein, albumin, absolute lymphocyte count, hand dynamometry, assessment of absorption 
for proteins, fats, and carbohydrates, morphometric study of small intestine mucosa biopsy 
specimens, count of hospitalizations due to CHF progression. 
Estimations of energy and nutrient demands were performed for all subjects before 
therapeutic diet and nutritional support were prescribed. 
Subjects in Group 2 had 25 % of their energy demands (daily energy consumption) covered 
using balanced nutritive mixes, and the remaining 75 % were covered using the standard 
diet. All patients maintained dietary diaries, which allowed us to control the amount of 
energy they have received with their usual diet.  
The balanced nutritive mixes used for nutritive support were Peptamen (Nestle, 
Switzerland), Berlamin Modular (Berlin-Chemie, Germany), Unipit and Nutrien-standard 
(Nutritek, Russia).  
Assessment of nutritional support efficacy included change of 6-minute test parameters over 
time, change of LBM over time, and number of hospitalizations due to CHF progression 
compared between the experimental group and the control group. 
During 24-week observation, a total of 11 patients died in 2 groups: 4 males and 2 females in 
Group 1 (standard-of-care), and 3 males and 2 females in Group 2 (oral nutritional support). 
Total number of hospitalization events throughout 24 weeks was 54 and 42 in Group 1 and 
Group 2, respectively. Table 3 shows causes of death and hospitalization. 
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Cause Hospitalization Death 
 Group 1 Group 2 Group 1 Group 2 
CHF progression 36 (66,7%) 28 (66,7%) 4 (66,7%) 3 (60%) 
Recurrent MI 6 (11,1%) 7 (16,7%) 1 (16,7%) 2 (40%) 
Pneumonias 10 (18,5%) 6 (14,3%) 1 (16,7%) 0 
Other 2 (0,4%) 3 (0,7%) 0 0 
Total 54 42 6 5 
Table 3. Causes of death and hospitalization for Groups 1 and 2. 
Three patients chose to withdraw from study: 2 of them were from the standard-of-care 
group, and another one from the nutritional support group (the reason was moving to 
another city). Compliance was assessed using patient diaries, where their adherence to basic 
therapy and to nutritional support was recorded. Compliance below 80 % was reported for 
2 subjects in Group 1 and 2 subjects in Group 2 (these subjects were excluded from the final 
analysis). As a result, in the standard-of-care group 26 patients completed the study, and in 
the nutritional support group 30 patients completed the study. 
1.4.1 Changes of 6-minute test parameters over time 
The trend for growth of the parameters in Group 2 was noticeable starting from Week 2. The 
curves of 6-minute test for the 2 groups diverged significantly starting from Week 8. After 
24 weeks, the exercise tolerance in patients receiving standard nutrition decreased 
significantly (p=0.025). The baseline values for 6-minute test in this group were 85 to 243 m, 
mean 203.4±41.6 m. After 24 weeks, the mean distance walked in 6 minutes decreased by 
19 % (164.7±48.1 m). 
Six patients with NYHA class III CHF experienced substantial deterioration of their health – 
worsening of dyspnea, weakness, edema, i. e. their condition progressed to NYHA class IV.  
In the group of patients receiving the nutritional support, the baseline for the 6-minute 
test was 182.2±45.6 m (range 34 m to 221 m), and Week 24 mean was 231.3±41.1 m (75 m 
to 295 m), i. e. a statistically significant (p=0.015) increase in exercise tolerance was 
observed. In this group, progression of NYHA class III to class IV was recorded for 
2 patients only.  
To conclude, in patients receiving the standard diet, Week 24 exercise tolerance decreased 
significantly, whereas in patients receiving nutritional support, significant increase of the 
exercise tolerance was observed. Statistical significance for the difference between the 
groups was p=0.021. 
1.4.2 Change of hand dynamometry measurements over time 
After 24 weeks of monitoring, no significant differences were found for dynamometry 
variables when comparing pre-treatment and post-treatment values; however, there was a 
trend towards increase for these variables in the nutritional support group (mean increase 
0.2 kg, p=0.084). In the standard-of-care group, the variables decreased, with mean change 
of 0.4 kg; this change was not statistically significant (p=0.09). 
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1.4.3 Change of LBM over time 
For most of the patients receiving nutritional support, a significant increase of LBM was 
shown (mean change 5.8±1.2 kg or 8.9 %, p=0.038). For 2 patients, a progressive decrease of 
LBM was recorded on treatment (the LBM decreased by 2.1 kg and 3.4 kg). In the standard 
nutrition group, 23 patients experienced statistically significant decrease of their LBM (mean 
decrease 3.6±0.7 kg or 4.9 %, p=0.036). The LBM did not change significantly in 2 patients, 
and an increase of LBM (+1.7 kg) was reported for 1 patient. 
To conclude, long-term nutritional support leads to statistically significant increase of LBM, 
while in the standard nutrition group the LBM continues to decrease progressively. The 
differences between groups were statistically significant (p=0.04). 
1.4.4 Changes of laboratory variables over time (absolute lymphocyte count and 
serum albumin) 
In the nutritional support group, a statistically significant increase of nutritional status was 
demonstrated: the absolute lymphocyte count increased from 1590 to 1710 x109 (+12.5 %, 
p=0.04), and the albumin level increased from 25.1 to 29.4 g/L (+17.1 %, p=0.045). In the 
standard-of-care group, no significant changes were observed after 24 weeks of monitoring 
for the lymphocyte count and albumin. The differences between groups were statistically 
significant (p=0.04). 
To conclude, the nutritional support demonstrated a favorable effect for all basic nutritional 
status variables. 
1.4.5 Other variables 
For the effect of nutritional support on protein, fat and carbohydrate absorption variables 
see Table 4. 
Absorption variables 
Group 1 Group 2 
Baseline Week 24 Baseline Week 24 
Total protein loss, 
% of daily consumption 
18.1±0.3 17.9±0.2 17.9±0.2 15.48±0.9 
Total fat loss, 
% of daily consumption 
22.5±0.6 21.6±0.4 23.4±0.4 
20.7±1.3 
 
D-xylose excretion with urine,
g/5 h 
0.81±0.05 0.85±0.04 0.82±0.04 0.83±0.04 
Table 4. Absorption of nutrients in patients with NYHA class III-IV CHF, pre-treatment and 
post-treatment. 
No statistically significant changes were demonstrated in either group for morphometric 
variables during the treatment period of 24 weeks. 
1.5 Conclusion 
The study of the small intestine condition revealed marked changes of structure and 
functional activity of the intestine in all patients with CHF. The degree of the small intestine 
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impairment directly depends on the severity of the CHF. This suggests direct impact of 
heart failure on gastrointestinal restructuring.  
We consider the oral nutrition system involving prescription of balanced nutritional mixes 
to be one of the promising options to treat cardiac cachexia, as it has a pathogenesis-based 
rationale. This study was an attempt to evaluate the efficacy of the nutritional support 
during CHF progression. 
2. Morphological and functional changes of the large intestine in patients 
with different classes of chronic heart failure 
2.1 Introduction 
Current understanding acknowledges the role of the following factors in the pathogenesis of 
CHF: neuroendocrine imbalance with excessive production of neurohormones, impairment 
of various target organs (cardiac muscle, kidneys, skeletal muscles, small intestine). 
However, many authors observed increased level of pro-inflammatory cytokines in CHF 
patients that cannot be explained by neuroendocrine activation. A number of authors 
reported a correlation between cytokine levels and blood plasma concentration of the 
endotoxin (lipopolysaccharide of gram-negative bacteria).  
In an attempt to find the origin of the endotoxin, various bacteria were considered, 
particularly the bacteria of upper and lower respiratory tract, H. pylori, microorganisms of 
urinary tract and intestine. The strongest changes were found in the flora of the large 
intestine, where increase of the total number of microorganisms was observed, 
predominantly gram-negative. However, there were no reports of detailed analysis of the 
intestinal flora composition, and the parietal mucin layer flora was not taken into account.  
The data on flora changes suggested potential methods of correction, particularly the 
selective decontamination method. However, according to literature reports, a course of 
selective decontamination reduces the number of microorganisms in the large intestine in 
the phase of antibacterial treatment only, while as early as 6 weeks after their 
discontinuation characteristics of the flora return to baseline. This shows lack of efficacy of 
the selective decontamination alone in CHF patients with high NYHA classes. 
From our perspective, there are two possible approaches to correct the endotoxemia that 
leads to systemic inflammation: (1) development of methods that act on the intestinal wall 
by decreasing its permeability to the endotoxin, and (2) treatment that has direct effect on 
the intestinal flora towards normalization of both numbers and the composition of the flora. 
2.2 Materials and methods 
Laboratory tests.  
Quantitative assay of endotoxin level using Kinetic-QCL test №50-650 U "Bioscience 
Cambrex Wallkersville", USA. 
Quantitative assay of IL-6 (IL-6 Human ELISA Kit (1 x 96 Well Plate), Cytokine company, 
Russia), TNF-alpha (TNF alpha Human ELISA Kit (1 x 96 Well Plate), Cytokine company, 
Russia), CRP (C Reactive Protein Human ELISA Kit - 1 x 96 Well Plate, Abcam, USA) 
plasma levels using solid phase ELISA. 
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2.3 Assessment of the microbial landscape, large intestine wall structure, endotoxin 
levels, and pro-inflammatory cytokines in CHF patients with different NYHA classes 
To study these variables, three consecutive groups were enrolled: Group 1: 65 patients with 
NYHA class III-IV CHF; Group 2: 60 patients with NYHA class I-II CHF; Group 3: 56 
patients, control group (patients with ischemic heart disease and arterial hypertension 
without signs of CHF).  
2.3.1 Changes in lumen flora of the large intestine in CHF patients with different NYHA 
classes and in the control group 
Comparison of the first and the second study groups revealed statistically significant 
differences (p<0.05) for the following variables: total number of enterobacteria was 109 colony-
forming units (CFU)/g in Group 1 vs. 107 CFU/g in Group 2. Enterobacteria pool growth was 
predominantly formed by E. coli (107 CFU/g in NYHA I-II group vs. 109 CFU/g in NYHA III-
IV group, p<0.0001), various Klebsiella sp. (105 CFU/g in NYHA I-II group vs. 107 CFU/g in 
NYHA III-IV group, p<0.005), and citrate-assimilating enterobacteria (106 CFU/g in NYHA I-II 
group vs. 108 CFU/g in NYHA III-IV group, p<0.005). Differences in concentrations of 
Citrobacters, Enterococci and Candida yeasts were also statistically significant.  
Comparison of the results for Group 1 (NYHA class III-IV) and control group subjects 
showed differences similar to the comparison of Group 1 versus Group 2, with the exception 
of differences in Clostridia populations (lecithinase- and hydrogen sulfide-positive strains): 
107 CFU/g in CHF patients with NYHA III-IV vs. 105 CFU/g in the control group (p<0.05).  
Comparison of Group 2 (NYHA I-II CHF) versus control group demonstrated minimal 
changes in the gut microbiome. Statistically significant differences were shown for 
Bacteroides only (109 CFU/g in NYHA class I-II patients vs. 1010 CFU/g in the control group, 
p<0.05). In CHF patients with NYHA class III-IV the levels of Bacteroides were not 
significantly different from results reported for the control group; therefore, from our 
perspective, these data can be ignored in practice.  
Statistically significant differences were demonstrated for Clostridia (hydrogen sulfide-
positive, lecithinase-positive): 105 CFU/g in the control group vs. 107 CFU/g in CHF 
patients with NYHA class III-IV, as well as for Enterococci and Candida yeasts (p<0.05). No 
statistically significant differences between groups were demonstrated for other 
microorganisms. 
Conclusion: the higher is NYHA class of CHF, the stronger are the changes in the large 
intestine flora due to growth of gram-negative species. 
2.4 Changes of the parietal mucin layer flora in CHF patients with NYHA class I-IV 
The microorganisms located in the parietal mucin layer have the most significant impact on 
the host. Therefore, our objective was to study the changes in parietal mucin layer flora in 
CHF patients with NYHA class I-IV.Taking into account the minimal changes in lumen flora 
between NYHA class I-II patients and the control group, and considering technical 
difficulties associated with parietal flora studies, we decided to skip investigation of parietal 
mucin layer flora in the large intestine for the control group.We decided to approximate the 
results from biopsies of CHF patients with NYHA class I-II as normal. 
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Biopsy studies showed changes similar to those reported for feces. A statistically significant 
changes of the enterobacteria population in CHF patients with NYHA class III-IV was 
demonstrated (108 CFU/g vs. 105 CFU/g in patients with NYHA classes III-IV and I-II, 
respectively; p<0.0001).These changes were due to growth of E. coli (108 CFU/g vs. 
105 CFU/g in NYHA III-IV vs. NYHA I-II, respectively; p<0.0001), Klebsiella (108 CFU/g vs. 
105 CFU/g in NYHA III-IV vs. NYHA I-II, respectively; p<0.005), and citrate-assimilating 
enterobacteria (108 CFU/g vs. 105 CFU/g in NYHA III-IV vs. NYHA I-II, respectively; 
p<0.005).No statistically significant differences were found in the biopsy specimens for 
Clostridia, Enterococci, as well as for Candida yeasts. However, statistically significant 
differences were demonstrated for the population of Bifidobacteria: 103 CFU/g vs. 106 CFU/g 
in NYHA III-IV vs. NYHA I-II, respectively (p<0.05). 
Conclusion: the parietal mucin layer flora changes corresponded to the changes of the 
lumen flora: the higher is NYHA class, the greater is the population of gram-negative 
microorganisms. No changes in the population levels of gram-positive flora was 
demonstrated for lumen flora, while in the parietal mucin layer a decrease of Bifidobacteria 
population was reported. 
2.5 Changes in the structure of the intestinal wall in CHF patients with NYHA class I-IV 
Changes found in the microbial landscape of both lumen flora and parietal mucin layer flora 
prompted us to study the large intestine wall structure in CHF patients with NYHA class I-
IV. 
In Group 2, no changes were observed in the biopsy specimens of large intestine mucosa. In 
Group 1, hyperemic vessels and focal dense lymphoid-cellular infiltrates were reported in 
the lamina propria of the large intestine mucosa (Fig. 4). This pattern is consistent with 
marked chronic inflammation.  
To confirm the lymphoid nature of the infiltrates, OLA reaction (common lymphocytic 
antigen) was performed (Fig. 5).  
A strong positive infiltrate (derivates of white blood cell line) was observed in the lamina 
propria of the large intestine mucosa. Particularly, intraepithelial lymphocytes were seen 
clearly. CD8+ staining (Fig. 6) revealed intraepithelial CD8+-positive T-lymphocytes in the 
superficial layer of the large intestine mucosa.  
Ki67 reaction revealed positive cells of gland epithelium (Fig. 7) in the proliferation phase. 
At the same time, there were solitary cells positive for Muc5 reaction (i. e. containing mucin 
5) in the superficial epithelium of the large intestine mucosa. 
Histopathology also revealed a large number of siderophages (Fig. 8), suggesting chronic 
congestion in the large intestine vessels. We considered these changes to be a sign of the 
chronic heart failure.  
Conclusion: the CHF patients with NYHA class III-IV showed signs of marked chronic 
inflammation in the large intestine mucosa, along with tissue edema and venous congestion. 
The severity of these changes increased with higher NYHA class and the severity of CHF 
decompensation symptoms. 
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Fig. 4. Biopsy sample of the large intestine mucosa. Hematoxylin-eosin stain. 
 
Fig. 5. Biopsy sample of the large intestine mucosa. OLA reaction. 
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Fig. 6. Biopsy sample of the large intestine mucosa, CD8+ lymphocyte stain. 1 – CD8+ 
lymphocytes. 
2.6 Endotoxin level assessment 
Plasma levels of the endotoxin were 1.2±0.03 EU/L in NYHA class III-IV subjects and 
0.46±0.01 EU/L in NYHA class I-II subjects (EU – endotoxin units). The level of the 
endotoxin in the control group subjects was 0.35±0.02 EU/L. Notably, plasma endotoxin 
levels directly correlated with the changes in population numbers of the large intestine 
gram-negative flora. 
The CHF patients with NYHA class III-IV had levels of IL-6 at 11.5±0.3 U/L, TNF-alpha at 
6.6±0.4 U/L, and CRP at 8±0.65 mg/ml. The CHF patients with NYHA class I-II had levels 
of IL-6 at 4.6±0.3 U/L, TNF-alpha at 3.7±0.4 U/L, and CRP at 5.5±0.29 mg/ml. The levels of 
these pro-inflammatory cytokines in the control group were within normal limits: : IL-6 was 
2 U/L, TNF-alpha was 1.5 U/L, and CRP was 2.9 mg/ml. The identified changes prompted 
us to suggest two approaches to correction of these conditions: 
1. Targeting the large intestine wall using different diuretic regimens, including agents 
with tissue activity. 
2. Selective decontamination in combination with probiotics. 
2.7 Use of different diuretic regimens 
Figure 9 shows the study design. 
1 
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Fig. 7. Biopsy sample of the large intestine mucosa, Ki67 reaction. 
1 – proliferating epithelial cells of a gland. 
The study drugs were prescribed for the first 5 days after the screening visit. After that, the 
study drug was discontinued and patients remained on the standard-of-care therapy for the 
30 days of follow-up (until compensation of their clinical status). 
The following tests were performed in this study: 
• body mass and the volume of excreted fluid, 
• results of 6-minute test,  
• Clinical Status Assessment Scale score (points), 
• plasma levels of the endotoxin, 
• feces flora composition and enzyme activity of the microorganisms, 
• results of colonoscopy with cecum biopsy and further histopathology and 
histochemistry of the obtained samples.  
These tests were performed on Day 1, Day 6 and Day 30 of the study. 
After the study treatment period, all patients were switched to the supportive care regimen 
and received the standard-of-care therapy; this phase lasted for 30 days.  
One patient died while on study (CHF decompensation was the cause of death). 
1 
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Fig. 8. Biopsy sample of the large intestine mucosa. Hematoxylin-eosin stain. 1 – 
siderophage. 
 
Fig. 9. Study design for the assessment of efficacy of Diacarb (acetazolamide) and 
Hypothiazide (hydrochlorothiazide) in comprehensive therapy of CHF patients with NYHA 
III-IV. 
Data from 79 subjects who completed the study was therefore used for the analysis of study 
results. 
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During the study, 15 adverse reactions were reported, but none of these caused 
discontinuation of the study treatment.  
No statistically significant differences between groups were demonstrated for the main 
variables. 
2.8 Changes of body mass and volume of excreted urine over time 
To determine efficacy of each study diuretic regimen, changes of the body mass and the 
volume of excreted urine were evaluated throughout the study. After the first five days, a 
decrease of body mass to 83±0.5 kg and 83.1±0.36 kg was demonstrated in both Group 1 and 
Group 2, respectively. The decrease was statistically significant against the baseline body 
mass of 87 kg, but the difference between groups was not statistically significant (p=0.872).  
The volume of excreted urine in the study groups was the highest on the first day of 
treatment, comprising 2.51±0.1 L and 2.5±0.25 L for Group 1 and Group 2, respectively. This 
effect decreased proportionally during the following five days in both groups. Notably, no 
statistically significant difference was detected between groups both in terms of body mass 
change (p=0.99) and in terms of the volume of excreted urine. 
2.9 Changes of endotoxin levels over time 
Substantial decrease of endotoxin levels on the follow-up Day 21 (1.2±0.02 EU/L to 
0.2±0.01 EU/L) was demonstrated in all groups. However, in the Diacarb group, this 
process was substantially faster: as early as on Day 5, the endotoxin levels were at 
0.4±0.02 EU/L, whereas in the thiazide diuretic group the levels were at 0.78±0.01 EU/L 
(p=0.012). Notably, while the diuretic effects in the Hypothiazide and Diacarb groups were 
almost identical, the latter group demonstrated faster decrease of the endotoxin level.  
This is probably due to tissue pH change caused by Diacarb, which facilitates fast 
dehydration of the large intestine wall and decreases its permeability for the endotoxin. To 
support this hypothesis, we performed histopathology and histochemistry studies using the 
biopsy samples from the large intestine at Day 1 and Day 5. To exclude the role of the large 
intestine flora, we also monitored its composition throughout the study. 
2.10 Assessment of diuretic regimen effects on structural changes in the large 
intestine wall over time 
Assessment of the histological and histochemical patterns in the large intestine mucosa 
during Diacarb or Hypothiazide treatment demonstrated the following changes.In the 
thiazide group (Fig. 10 and Fig. 11), there were signs of reduced mucosal edema on 
treatment (Day 6); however, a rise of local inflammatory reaction was also evident 
(lymphoplasmocytic infiltration, increased number of segmented WBCs, predominantly 
eosinophils).This may be a relative effect caused by reduction of edema and shortening of 
intercellular distances rather than an absolute growth of the inflammatory infiltration. 
A decrease of edema on Day 6 was also seen in the Diacarb group (Fig. 12, Fig. 13), but, in 
addition to that, the level of local inflammation decreased (the infiltration by lymphoid cells 
is consistent with low-intensity chronic inflammation). 
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Most probably, the difference between Diacarb and Hypothiazide in their effects on large 
intestine wall edema causes different permeability of the wall for the endotoxin, which 
results in different kinetics of blood endotoxin level reduction in the CHF patients with 
NYHA class III-IV. These findings may result from changes in pH of the intestinal wall, 
better microcirculation, and consequent decrease of infiltration. Another possibility is that 
Diacarb, a carbonic anhydrase inhibitor, blocks alpha-carbonic anhydrase of gram-negative 
bacteria, depressing their pathogenic effect on the intestinal wall. 
2.11 Assessment of effects of diuretic regimens on changes of flora over time 
No statistically significant changes in concentration of gram-negative bacteria both in feces 
and in biopsy material were demonstrated, regardless of the treatment regimen. 
 
Fig. 10. Magnification x 400 (good), hematoxylin and eosin stain.Before treatment, “fuzzy” 
lymphoid-cellular infiltration and solitary eosinophils were noted in the lamina propria of the 
large intestine mucosa. 
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Fig. 11. Magnification x 400 (good), hematoxylin and eosin stain.Day 6 of the treatment 
period.Lymphoplasmocytic infiltration increases. The population of segmented WBCs, 
particularly eosinophils, increases significantly. 
These results demonstrate that plasma endotoxin levels in CHF patients with NYHA 
class III-IV are affected not only by the gram-negative flora population in the intestine, but 
also by the severity of edema, and therefore by the degree of decompensation of patient’s 
clinical status.The endotoxin levels in this case are probably affected by the increase of the 
intestinal wall permeability for the endotoxin caused by the edema. 
As patient’s status improves towards compensation, the endotoxin levels decrease to normal 
values. This process is faster with the use of Diacarb compared to the use of Hypothiazide. 
However, this is not accountable to their diuretic effects, because there were no statistically 
significant differences in the changes of body mass and the volume of excreted urine 
between Diacarb and Hypothiazide.It is likely that Diacarb improves microcirculation by 
changing tissue pH, and causes not only improvement of renal urine filtration, but also 
faster shrinking of tissues, particularly shrinking of the intestinal wall, which decreases its 
permeability for the endotoxin. 
Differences in the inflammatory infiltrate intensity between Hypothiazide and Diacarb 
groups were discovered (in addition to decreased edema, Diacarb reduces the inflammation 
in the large intestine mucosa). This effect is probably accountable to improved 
microcirculation in the intestinal wall in the Diacarb group, as well as carbonic anhydrase 
inhibition produced by Diacarb leading to block of alpha-carbonic anhydrase of gram-
negative bacteria, which reduces their pathogenic effect on the intestinal wall. 
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Fig. 12. Magnification x 400 (good), hematoxylin and eosin stain.Before treatment, there 
were hyperemic vessels and focal dense lymphoid-cellular infiltration in the lamina propria 
of the large intestine. This pattern is typical for strong chronic inflammation. 
 
Fig. 13. Magnification x 400 (good), hematoxylin and eosin stain. Day 6 of the treatment 
period.“Fuzzy” lymphoid-cellular infiltration is seen in the lamina propria of the large 
intestine mucosa, which is consistent with the pattern of weak chronic inflammation. 
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Conclusion: administration of Diacarb facilitates faster decrease of plasma endotoxin levels, 
which allows for faster compensation of patient’s clinical status. 
2.12 Use of selective decontamination alone vs. selective decontamination in 
combination with probiotics in comprehensive therapy of NYHA class III-IV CHF 
All patients included in this phase of the study received standard-of-care therapy, 
including: 
• ACE inhibitors/ angiotensin receptor blockers (mean daily dose of 10 mg/160 mg); 
• beta-blockers (prescribed from Day 5 after the start of the therapy, dose titration from 
the minimum therapeutic dose, mean daily dose was 50 mg of metoprolol per day); 
• digoxin 0.00025 g per day (in case of atrial fibrillation with tachycardia or LVEF below 
25 %); 
• aspirin 125 mg/day (secondary prophylaxis method); 
• Cordarone 200 mg/day (in case of ventricular disturbances with risk of high Lown 
grades); 
• loop diuretics (Lasix) with mean daily dose of 70 mg/day. 
The following drugs were chosen for the study: 
• antibacterial fluoroquinolone: ciprofloxacin with daily dose of 1000 mg; 
• probiotic: Primadophilus Bifidus, 1 capsule per day. 
At the study start, all patients received a 5-day selective decontamination with oral 
ciprofloxacin 1000 mg/day.After that, patients were randomized into two groups: 
• Group 1 (n=45) received standard-of-care; 
• Group 2 (n=45) received the probiotic – Primadophilus Bifidus, 1 capsule per day for 
14 days. 
After the completion of probiotic treatment, both groups received standard-of-care. 
The following study variables were evaluated on Day 1, Day 5, and Day 21: 
• results of 6-minute test, 
• Clinical Status Assessment Scale score (points), 
• plasma levels of the endotoxin, 
• feces flora composition and enzyme activity of the microorganisms. 
In this phase, 2 deaths occurred in the group receiving selective decontamination alone.In 
the Primadophilus Bifidus group, one patient experienced adverse effects leading to 
patient’s decision to discontinue the drug. 
Data from 87 subjects who completed the study was therefore used for the analysis of study 
results. 
Ten cases of adverse reactions were reported during the study. Only one of these cases 
caused the patient to stop the drug. 
The resulting groups had comparable basic characteristics. 
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2.13 Changes of the large intestine flora over time with the use of selective 
decontamination alone or selective decontamination combined with the probiotic 
By Day 5 of the study, a statistically significant decrease was demonstrated in Group 1 for 
total population of both gram-negative microorganisms (baseline value was 1012±0.1 CFU/g, 
the value after the selective decontamination was 106±0.4 CFU/g; p=0.000) and gram-positive 
microorganisms (baseline value was 106±0.56 CFU/g, the value after the selective 
decontamination was 104±0.32 CFU/g; p=0.000)However, on Day 21 study visit, gram-
negative and gram-positive populations returned to their baseline levels (1011.9 CFU/g and 
106.1 CFU/g, respectively; p=0.000). These results support literature reports of low efficacy 
of the selective decontamination used alone. 
In the group where probiotics were prescribed after the course of selective decontamination, 
Day 5 populations decreased similarly to Group 1, both for gram-negative (baseline 
1012.05±0.6 CFU/g, post-decontamination 106.3±0.4 CFU/g; p=0.000) and gram-positive 
(baseline 105.2±0.5 CFU/g, post-decontamination 104.2±0.2 CFU/g; p=0.000) 
microorganisms.However, after Primadophilus Bifidus administration for 14 days, gram-
positive flora population grew to 108.02±0.1 CFU/g, and an insignificant growth of gram-
negative flora to 107.27±0.1 CFU/g was demonstrated, which is consistent with normal values 
for gram-negative population in the large intestine. 
Conclusion: administration of probiotics after a course of selective decontamination 
normalizes large intestine flora levels, whereas decontamination alone leads to reduction of 
microbial populations for a short term only. 
2.14 Changes of the endotoxin level over time 
In Group 1, Day 5 endotoxin levels decreased from baseline significantly (baseline: 
1.2±0.9 EU/L, Day 5: 0.55±0.06 EU/L; p=0.000), which corresponded to the reduction of 
gram-negative population in the large intestine. However, at Day 21, as the gram-negative 
population in the large intestine grew, the plasma endotoxin levels returned to their baseline 
values (1.18±0.05 EU/L); on Day 30, the endotoxin concentration remained high 
(1.21±0.045 EU/L). 
In Group 2, after the selective decontamination was completed and the gram-negative 
population in the large intestine reduced, the plasma endotoxin levels also declined 
(baseline: 1.24±0.01 EU/L, Day 5: 0.67±0.03 EU/L, p=0.000). A trend towards decline of 
plasma endotoxin levels and achievement of normal values was demonstrated subsequently 
(Day 21: 0.56±0.02 EU/L, Day 30: 0.26±0.08 EU/L). These results can be explained by the 
reduction of the gram-negative populations in the large intestine due to administration of 
the selective decontamination followed by probiotic. 
2.15 Assessment of changes in plasma pro-inflammatory cytokine levels over time 
With the use of the selective decontamination alone, the decrease of the following variables 
on Day 5 was demonstrated: IL-6 to 4.1±0.03 U/L (baseline 4.9±0.01 U/L), TNF-alpha to 
5±0.09 U/L (baseline 5.7±0.04 U/L), and CRP to 4 mg/ml (baseline 8.6 mg/ml).However, as 
early as on Day 12, these cytokine variables were shown to return to their baseline levels, 
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which persisted till Day 30. This demonstrates poor efficacy of the selective decontamination 
alone for the system inflammation marker endpoints. 
When the selective decontamination was used in combination with the probiotic, decrease in 
the population of enterobacteria in the large intestine and decrease of plasma endotoxin 
levels were reported.However, while levels of the pro-inflammatory cytokines decreased by 
Day 5 (CRP: 4.2±0.1 mg/ml on Day 5 vs. baseline 7.82±0.05 mg/L; IL-6: 3.9±0.05 U/L on 
Day 5 vs. baseline 5±0.01 U/L; TNF-alpha: 5.01±0.02 U/L on Day 5 vs. baseline 
5.8±0.02 U/L), but on Day 21 they already rebounded above the baseline levels, and on 
Day 30 there was a trend towards further growth of their levels. 
This is probably accountable to the decrease of gram-negative flora population in the large 
intestine due to the antibacterial treatment, and consequent decline of plasma levels of the 
endotoxin.Normal population numbers of the gram-negative flora are further maintained by 
the administration of the probiotic. However, the probiotic contains gram-positive 
microorganisms, which bind to the Toll-like receptors, initiating the synthesis of pro-
inflammatory cytokines in the large intestine enterocytes, leading to further exacerbation of 
the systemic inflammation. 
These results demonstrate lack of efficacy for the selective decontamination used 
alone.When the selective decontamination was combined with the probiotic, normalization 
of the intestinal flora and plasma endotoxin levels was reported. However, a significant 
growth of the pro-inflammatory cytokine levels occurs with this regimen, which affects 
patient’s status and is likely to require additional correction. 
These data demonstrated that comprehensive therapy for CHF combined with the selective 
decontamination alone (i. e. without probiotic) caused to a short-term decline of gram-
negative flora population, while the population numbers of gram-positive flora remained 
almost unaffected. A short-term decline in plasma levels of the endotoxin and pro-
inflammatory cytokines was also reported. However, as early as one week after the 
discontinuation of the antibacterial treatment, gram-negative flora population numbers 
returned to their baseline levels, accompanied by the increase in plasma levels of the 
endotoxin and the pro-inflammatory cytokines. A potential explanation for this pattern is 
that CHF patients with NYHA class III-IV develop significant restructuring of their large 
intestine walls, providing favorable conditions for domination of gram-negative 
flora.Isolated use of the selective decontamination, neither supported by any agents that 
repair large intestine wall structure, nor combined by any probiotics, fails to provide stable, 
long-term changes in the large intestine flora. 
However, administration of probiotics added to the antibacterial treatment demonstrated 
persistent effect: normalization of gram-negative flora levels and plasma endotoxin levels. 
Notably, with the use of the probiotic, blood CRP levels increased, which is probably 
accountable to the presence of gram-positive flora in the probiotic, prompting the host to 
produce more antibodies. Unfortunately, the CRP levels were not followed for a longer 
period of time, and the time needed for the CRP to reach normal levels remained 
unknown.It can only be assumed that this period should not take too much time, because 
the subjects were exposed to the probiotic for 2 weeks only. However, if a long-term, 
persistent growth of the CRP levels in blood do occur, decompensated CHF patients with 
NYHA class III-IV might benefit from administration of statins. 
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3. Clinical significance of adipose tissue changes over time in patients with 
chronic heart failure of ischemic origin. Treatment options 
3.1 Introduction 
Syndrome of cardiac cachexia is one of the most severe complications of chronic heart 
failure. Among the latest advancements in the field of immunology is the concept of 
cytokine activation system and its role in the pathogenesis of chronic heart failure and 
development of cardiac cachexia. Currently, two main classes of cytokines are known to 
participate in the development of heart failure:vasoconstrictive cytokines (endothelin-1 and 
big endothelin) and vasodepressive cytokines (TNF-ǂ, IL-1, IL-6, IL-8). Patients with signs of 
cardiac cachexia are known to have higher levels of inflammation markers than patients 
with normal body mass (Francis, 1998; Monteiro, 2007). Notably, adipose tissue is one of the 
sources of cytokines.In addition to leptin and adiponectin, adipose tissue was demonstrated 
to participate in production of TNF-ǂ and IL-6 (Moses, 2004; Nagaya, 2001; Springer, 2010). 
We assumed that one of the methods to decrease the activities of pro-inflammatory 
cytokines could be the increase of dry body mass (body muscle mass, body fat mass) 
(Dostalova et al., 2003). Therefore, one of the options to correct the levels of inflammatory 
markers in this category of patients could be nutritional support. 
From our perspective, there are two possible approaches to correct the systemic 
inflammation:development of methods that can increase the mass of the adipose tissue and 
methods that have direct effect on the synthesis of pro-inflammatory cytokines. 
3.2 Assessment of body composition, levels of leptin, adiponectin, and pro-
inflammatory cytokines in patients with different NYHA classes of CHF 
To study these variables, three consecutive groups were enrolled in the first part of the 
study: Group 1 included chronic heart failure patients with NYHA class I-II, Group 2 
included chronic heart failure patients with NYHA class III-IV (subgroup A: without 
cachexia; subgroup B: with cachexia), Group 3 was a control group.Patient screening was 
performed in the population of patients with history of CHF of ischemic origin with 
NYHA class I-IV for more than 6 months, older than 40 years of age, admitted to a general 
internal medicine department or a cardiology department (n=197).The control group 
included outpatients of the Consultation and Diagnostics Polyclinic (n=52). 
Clinical characteristics of the patients: 
Age:these three groups were comparable in terms of patients’ age. 
From the results of analysis of associated clinical conditions, diabetes mellitus was reported 
in 57.1 % of CHF patients with NYHA class III-IV with cachexia and in 48.6 % without 
cachexia, as well as in 14 % of patients with NYHA class I-II. 
Analysis of concomitant medications: CHF patients with NYHA class III-IV with/without 
cachexia were on ACE inhibitors or ARB in 64.2 %/63.8 %, on beta-adrenoblockers in 
82.1 %/80 %, on digoxin in 75 %/76.1 %, on diuretics in 35.7 %/34.3 %, and on Cordarone in 
28.6 %/19.5 % of cases, respectively.For NYHA class I-II patients, the corresponding 
variables were: on ACE inhibitors/ARB 51.6 %, on beta-adrenoblockers 59.4 %, on digoxin 
9.3 %, on diuretics 45.3 %, on Cordarone 3.1 %. 
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3.3 Comparison of methods used to evaluate body composition in patients with CHF 
of different NYHA class and the control group patients 
Two methods were used to study body composition: caliper measurement and 
bioimpedance analysis.Comparison of these methods in all three groups did not reveal any 
statistically significant differences between the values obtained using caliper measurements 
and bioimpedance analyzer.However, the method of caliper measurements is subjective and 
is not suitable for patients with decompensated heart failure (i. e. with severe edema 
syndrome).Moreover, unlike caliper measurements, bioimpedance analyzer of body 
composition allows to estimate not only the body fat mass, but also total fluid content, 
which is important for the assessment of the body composition in patients with 
decompensated chronic heart failure. 
Comparison of Group 1 vs. Group 2 revealed statistically significant differences in the 
adipose tissue mass, which was 29.7±2.2 kg in Group 1 and 22.2±2.1 kg in Group 2 (p<0.001), 
as well as in the lean body mass, which was 54.8±6.9 kg in Group 1 and 59.7±6.1 kg 
(p<0.001) in Group 2. This was associated with changes in total fluid content, which was 
38.2±3.1 kg in Group 1 vs. 48.8±3.3 kg in patients with NYHA class III-IV (p<0.001).BMI did 
not differ significantly between groups. 
Comparison of the study results between Group 2 (NYHA III-IV) and the control group 
revealed changes similar to those between Group 1 and Group 2. 
Comparison of Group 1 (NYHA I-II) vs. the control group revealed statistically significant 
differences in the body fat mass, which was 29.7±2.2 kg in Group 1 vs. 32.6±2.4 kg in 
Group 3 (p<0.001), and statistically significant differences in total fluid content, which was 
38.2±3.1 kg in Group 1 vs. 25.6±2.9 kg in Group 3 (p<0.001). 
In patients with cachexia, a significantly lower LBM of 55.2±4.9 kg and body fat mass of 
15.65±1.8 kg were reported. Notably, the total fluid content levels in these patients was 
greater than levels of this variable in patients without cachexia, but the differences of this 
variable were not statistically significant. 
Conclusion: the higher is NYHA class of CHF, the stronger are changes of body 
composition; with higher NYHA class, adipose tissue mass declines, total fluid content 
grows.These changes were stronger in patients with cachexia. 
3.4 Levels of leptin, adiponectin, and pro-inflammatory cytokines in patients with 
different NYHA classes and in the control group 
The patients with NYHA III-IV were found to have adiponectin levels at 18.6±4.9 µg/mL, 
leptin levels at 43.8±8.3 ng/mL, IL-6 levels at 11.7±0.3 U/L, TNF-ǂ levels at 6.6±0.2 U/L, 
CRP levels at 8.8±0.4 mg/ml. These values were significantly higher than values reported 
for patients with NYHA class I-II and for patients in the control group, who had their levels 
of adipokines and pro-inflammatory cytokines within normal range. 
Comparison of patients with NYHA class III-IV with and without cachexia demonstrated 
the following differences: leptin levels were significantly higher in patients without cachexia 
(47.9±4.2 ng/mL), while levels of adiponectin, IL-6, TNF-ǂ, and CRP were significantly 
higher in patients with cachexia. 
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Conclusion: the higher is NYHA class of CHF, the stronger is the intensity of chronic 
inflammation. While this may be an effect of growing intoxication in patients with advanced 
stages of CHF, this could also be associated with the role of the adipose tissue in production 
of pro-inflammatory cytokines and biologic agents that stimulate cytokine production. 
Higher classes of NYHA are associated with lower adipose tissue mass, which leads to 
increase of adiponectin plasma levels.However, the levels of leptin in patients with NYHA 
class III-IV are also high, which may be accountable to big dimensions of adipocytes. 
Patients with cachexia have significantly lower levels of leptin when compared to patients 
without cachexia; this is probably associated with shrinking of the lipid droplet in the 
adipocyte. 
3.5 Evaluation of visceral and subcutaneous tissue structure in patients with different 
CHF classes 
To study this variable, autopsies of deceased patients (with NYHA class I-IV chronic heart 
failure diagnosed before their death) were performed. Patients were allocated into two 
groups: Group 1: before death, patients were diagnosed with NYHA I-II chronic heart 
failure; Group 2: before death, patients were diagnosed with NYHA III-IV chronic heart 
failure. Patients of Group 2 were divided in two subgroups: patients with cachexia and 
patients without cachexia. All patients were admitted to GKB no. 4 (City Clinical Hospital 
no. 4) before death. For NYHA I-II patients, the main reasons for hospitalization were: 
unstable angina, acute myocardial infarction, hypertensive crisis, heart rhythm disorder, 
cerebrovascular accident; for NYHA III-IV patients, the main reasons for hospitalization 
were: decompensation of CHF, acute/recurrent myocardial infarction, heart rhythm 
disorder, cerebrovascular accident.The postmortem assessment included measurement of 
the subcutaneous fat, measurement of the omentum mass, morphometric study of the 
subcutaneous fat, omental fat and pericardial fat. 
Of 118 subjects total, 50 subjects were in the first group, 56 subjects were in the second 
group, and 12 subjects belonged to the third group. These three groups were comparable in 
terms of patients’ age. The main cause of death for NYHA I-II patients was the acute 
myocardial infarction (46.0 %), and for NYHA II-III patients (both with cachexia and 
without cachexia) the main cause of death was post-infarction cardiosclerosis (58.3 %, 
48.2 %, respectively). The most frequent complication leading to death in patients with 
NYHA class I-II CHF was acute heart failure; in patients with NYHA class III-IV the most 
frequent complication leading to death was CHF decompensation. Pneumonia incidence in 
patients with NYHA class III-IV was higher (22 %) than in NYHA I-II patients (4 %). 
Multiple complications were reported for 22.0 % patients with NYHA I-II, 46.4 % patients 
with NYHA III-IV without cachexia, and 100 % of patients with NYHA III-IV with cachexia. 
During autopsy, the following investigations were performed: measurement of 
subcutaneous fat thickness 2 cm below the navel, measurement of omentum weight; 
autopsy samples of subcutaneous fat, omental fat, and pericardial fat at the apex of the heart 
were collected. 
There were no statistically significant differences between patients with NYHA I-II and 
NYHA III-IV without cachexia in the thickness of subcutaneous fat: it was 5.3±1.7 cm and 
5.1±2.2, respectively (p=0.6).In CHF patients with NYHA III-IV with cachexia, the difference 
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in thickness of subcutaneous fat (2.4±1.1 cm) was statistically different from NYHA III-IV 
patients without cachexia (p<0.001). 
In CHF patients with NYHA class III-IV, omentum weight was significantly lower than in 
patients with NYHA I-II (387±134 g vs. 521±142 g, respectively; p<0.001).In CHF patients 
with NYHA classes III and IV, the omentum weight was 164±87 g, which is significantly 
lower than in patients without cachexia (p<0.001). 
The morphometric analysis of the samples showed the following changes.In the 
subcutaneous fat, lymphocytic infiltration was the strongest in patients with NYHA class III-
IV with cachexia (average 12.4±4.7 %); in patients with NYHA class I-II this variable was 
3.8±2.2 % (comparison: p<0.001), and in NYHA III-IV patients without cachexia it was 
4.3±2.4 % (comparison: p<0.001).No significant differences in the proportion of fibrous 
tissue in the subcutaneous fat was found between the groups.The percentage of fibrous 
tissue was 3.8±1.9 % in NYHA class I-II patients, 4.1±2.3 % in NYHA class III-IV patients 
without cachexia, and 4.6±2.6 % in NYHA class III-IV patients with cachexia (p1-2=0.469, p1-
3=0.229, p2-3=0.506). See Fig. 14, 15, 16. 
 
Fig. 14. Subcutaneous fat in a CHF patient with NYHA class I. Romanowsky-Giemsa stain. 
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Fig. 15. Subcutaneous fat in a CHF patient with NYHA class III. 
 
Fig. 16. Subcutaneous fat in a CHF patient with NYHA class IV with cachexia. 
Romanowsky-Giemsa stain. 
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Analysis of the visceral fat (omentum, pericardial fat) showed the strongest lymphocytic 
infiltration in subjects with NYHA class III-IV, both with cachexia and without cachexia. 
This variable was 53.4±7.8 % in the omentum and 49.7±8.4 % in the pericardium in patients 
with cachexia, and 42.1±6.7 % in the omentum and 42.6±8.8 % in the pericardium in patients 
without cachexia (compare to patients with NYHA I-II, who had the lymphocytic infiltration 
of 5.1±2.3 % in the omentum (p1<0.001, p2<0.001) and 4.9±2.6 % in the pericardium 
(p1<0.001, p2<0.001)).The amount of fibrous tissue in NYHA class III-IV patients without 
cachexia was higher than in the patients with NYHA class I-II: 15.2±4.9 % vs. 3.1±1.2 % in 
the omental adipose tissue (p<0.001), 14.8±5.4 % vs. 3.2±0.9 % in the adipose tissue of the 
pericardium (p<0.001), respectively.In NYHA III-IV patients with cachexia, the amount of 
fibrous tissue was significantly higher than in NYHA III-IV patients without cachexia: 
24.8±3.7 % in the omentum (p<0.001) and 24.3±3.2 % in the pericardium (p<0.001).See 
figures 17-22. 
Mean diameter of adipocytes was measured, with the following results:In CHF patients 
with NYHA class I-II, the diameter of adipocytes was 38.6±12.2 µm in the subcutaneous fat 
samples, 44.2±16.1 µm in the omentum, 42.3±11.4 µm in the pericardial fat. In CHF patients 
with NYHA class III-IV without cachexia, the diameter of adipocytes was 42.7±14.2 µm in 
the subcutaneous fat samples (p=0.116), 56.4±13.9 µm in the omentum (p<0.001), 52.2±11.3 
µm in the pericardial fat (p<0.001). In NYHA class III-IV patients with cachexia, the 
diameter of adipocytes was 28.2±11.5 µm in the subcutaneous fat samples (p=0.01), 
32.8±14.3 µm in the omentum (p=0.028), 30.3±12.4 µm in the pericardial fat (p<0.001). 
 
Fig. 17. Visceral adipose tissue (pericardial fat) in a CHF patient with NYHA class I. 
Romanowsky-Giemsa stain. 
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Fig. 18. Visceral adipose tissue (omentum) in a CHF patient with NYHA class I. 
Romanowsky-Giemsa stain. 
 
Fig. 19. Visceral adipose tissue (pericardial fat) in a CHF patient with 
NYHA class III.Romanowsky-Giemsa stain. 
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Fig. 20. Visceral adipose tissue (omentum) in a NYHA class III patient without cachexia. Van 
Gieson’s stain. 
 
Fig. 21. Visceral adipose tissue (pericardial fat) in a CHF patient with NYHA class IV with 
cachexia.Romanowsky-Giemsa stain. 
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Fig. 22. Visceral adipose tissue (omentum) in a NYHA class IV patient with cachexia. Van 
Gieson’s stain. 
Therefore, the higher is NYHA class, the lower are the subcutaneous fat and the omentum 
weight. The higher is NYHA class, the more intensive is the chronic inflammation, 
manifested by the lymphocytic infiltration and the content of fibrous tissue, especially in the 
visceral fat.These changes are stronger in NYHA III-IV patients with cachexia. 
In patients with NYHA III-IV and cachexia, a decrease in the content of adipose tissue was 
demonstrated to be the result of adipocyte shrinking, as well as substitution of the adipose 
tissue by fibrous tissue. 
Currently, there is no solution for the problem of how to increase the body muscle mass and 
body fat mass in patients with cachexia, particularly with cardiac cachexia. Unfortunately, 
all attempts to use anabolic steroids in this patient population have been unsuccessful.We 
assumed that using nutritional support in this patient population would allow to change the 
nutritional status in addition to reducing the malabsorption syndrome. Moreover, 
nutritional mixes that have both local and systemic anti-inflammatory effect are currently 
available. Administration of these mixes might help fighting the inflammation observed in 
the large intestine of the CHF patients with higher classes of NYHA, as well as reducing 
their blood levels of pro-inflammatory cytokines. 
3.6 Comparison of efficacy of Modulen vs. Peptamen added to standard-of-care 
therapy in CHF patients with NYHA III-IV 
Screening was performed in a consecutive population of patients hospitalized to general 
internal medicine or cardiology departments (n=144). 
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Inclusion and exclusion criteria are shown in Table 5. 
Inclusion criteria Exclusion criteria 
• CHF of ischemic origin 
• CHF history for more than 12 months 
• Age > 40 years old 
• Patient’s consent to participation in the study 
• Acute or chronic infectious diseases 
• Cancer within last 5 years 
• Severe impairment of liver or kidneys 
(AST, ALT > 3 x upper limit of normal, 
creatinine > 250 µmol/L) 
• Mental disorders 
• Primary or secondary 
immunodeficiency conditions 
• Alcohol or substance dependence 
• Any conditions that can cause 
cachexia (at investigator’s discretion) 
• Lack of tolerance to enteral nutrition 
regimen 
• Unable to sign the informed consent 
• Unable to follow the study procedures 
Table 5. Inclusion and exclusion criteria. 
Chronic heart failure patients with NYHA class III-IV were randomized into three groups, 
40 subjects in each: 
- Patients in Group 1 received Modulen (balanced nutritional mix for enteral tube feeding 
or oral feeding) in addition to standard-of-care therapy. 
- Patients in Group 2 received Peptamen (balanced nutritional mix for enteral tube 
feeding or oral feeding) in addition to standard-of-care therapy. 
- Patients in Group 3 received the standard-of-care therapy only, as well as the necessary 
amount of nutrients in a standard diet designed for cardiology patients. 
All patients received standard-of-care therapy, which included: 
• ACE inhibitors/ angiotensin receptor antagonists (mean daily dose of 10 mg/160 mg); 
• beta-blockers (prescribed from Day 5 after the start of the therapy, dose titration from 
the minimum therapeutic dose, mean daily dose was 12.5 mg of carvedilol per day); 
• digoxin 0.00025 g per day (in case of atrial fibrillation with tachycardia or sinus rhythm 
with LVEF below 25 %); 
• aspirin 125 mg/day (secondary prophylaxis method); 
• loop diuretics (Lasix) with mean daily dose of 60 mg/day. 
The following procedures were performed for every patient:medical history; physical 
examination, including measurement of weight, height, waist circumference, hip 
circumference, wrist circumference, arm circumference; casual BP; heart rate; fasting 
chemistry lab blood samples; 6-minute test; echocardiography for the measurement of the 
ejection fraction; caliper measurements; bioimpedance analysis of body composition to 
measure the lean body mass (LBM), body fat mass (BFM), total water content (TW); Clinical 
Status Assessment Score. 
Group 1 patients received nutritional mix Modulen (100-130 g of dry mix), which accounted 
for 25 % of their daily energy demands, in addition to their basic diet.Group 2 patients 
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received nutritional mix Peptamen (100-130 g of dry mix), which accounted for 25 % of their 
daily energy demands, in addition to their basic diet.Group 3 patients received their 
standard therapy only, as well as the necessary amount of nutrients within a standard diet, 
based on pre-calculated energy demands.All patients maintained their dietary diaries, 
which were used to adjust the diet on an individual basis. 
The energy demands were calculated using Harris-Benedict formula with adjustment for 
body mass deficit, taking into account body temperature and activity of a patient. 
Energy demands: 
 AEC = EOO*AF*TF*BMD (1) 
where:AEC — actual energy consumption (kcal/day); 
EOO — basal metabolic rate, calculated using Harris-Benedict equations: 
EOO (men) = 66 + (13.7*body mass, kg) + (5*height, cm) – (6.8*age) 
EOO (women) = 655 + (9.6*body mass, kg) + (1.8*height, cm) – (4.7*age) 
AF — activity factor (bed rest: 1.1, movement within room: 1.2, no limitations: 1.3), TF — 
temperature factor (36–37.0°C: 1.0, 37.1–38.0°C: 1.1, 38.1–39.0°C: 1.2), BMD — body mass 
deficit (10–20 %: 1.1, 20–30 %: 1.2, >30 %: 1.3). 
This study enrolled 120 patients.Males: 18 subjects (45 %) in Group 1, 19 subjects (47.5 %) in 
Group 2, and 21 subjects (52.5 %) in Group 3.Females: 22 subjects (55 %) in Group 1, 21 
subjects (52.5 %) in Group 2, and 19 subjects (47.5 %) in Group 3. 
Total duration of CHF history was 15.3±4.3 months, 15.7±4.1 months, and 15.6±4.4 months 
for Group 1, Group 2, and Group 3, respectively.These characteristics were not significantly 
different between study groups. 
Compensated type 2 diabetes mellitus was reported in 52.5 %, 55 %, and 42.5 % of subjects 
in Group 1, Group 2, and Group 3, respectively. 
Charlson index was > 5 in all groups. 
As demonstrated above, there were no statistically significant differences between groups in 
gender, age, and co-morbidity rates. 
In all three groups, decreases of weight and LBM were demonstrated on Day 21 of the 
treatment period:in Group 1, Day 21 body weight was 56.4±2.6 kg (baseline 66.9±3.5 kg); in 
Group 2, Day 21 body weight was 56.4±2.1 kg (baseline 66.2±2.9 kg); in Group 3, Day 21 body 
weight was 55.4±1.7 kg (baseline 67.0±2.9 kg); in Group 1, Day 21 LBM was 40.9±1.7 kg 
(baseline LBM 47.2±1.9 kg); in Group 2, Day 21 LBM was 42.0±2.0 kg (baseline LBM 47.3±2.0 
kg); in Group 3, Day 21 LBM was 41.2±1.9 kg (baseline LBM 46.9±1.8 kg).However, on Day 
224, the body weight in Group 1 increased to 62.6±2.7 kg, but was significantly lower than in 
Group 2 (66.8±2.4 kg) and Group 3 (68.7±1.9 kg).The LBM also increased on Day 224, but it 
was lower than baseline LBM in Group 1 (44.4±1.6 kg), whereas it reached the baseline in 
Group 2 (47.4±2.2 kg) and significantly exceeded the baseline in Group 3 (48.1±1.9 kg). 
In Group 2 and Group 3, a statistically significant decrease of total fluid content on Day 21 
was demonstrated: 34.6±1.8 kg in Group 2 (baseline 47.3±2.1 kg) and 34.4±1.7 in Group 3 
www.intechopen.com
Morphology and Functional Changes of Intestine,  
Trophology Status and Systemic Inflammation in Patients with Chronic Heart Failure 
 
417 
(baseline 47.1±1.7 kg).On Day 224, the total fluid content increased in both of these groups: 
47.2±2.0 kg and 48.3±1.9, respectively.In Group 1, the total fluid content also decreased by 
Day 21 (34.3±1.9 kg) compared to baseline (46.8±2.0 kg), but there was no significant 
increase of the total fluid content on Day 224 (39.3±1.9 kg), unlike in other two groups. 
On Day 224, the body fat mass increased significantly in Group 1 to 18.6±1.11 kg (baseline 
16,8±1.13 kg), while no significant change in the body fat mass was reported for Group 2 
and Group 3:16.8±1.13 kg (baseline 16.5±1.16 kg) in Group 2 and 16.6±1.33 kg (baseline 
16.5±1.19 kg) in Group 3. 
On Day 21, the BMI decreased from baseline in all groups:21.2±0.60 kg/m2 in Group 1 
(baseline 24.1±0.93 kg/m2); 21.4±0.59 kg/m2 in Group 2 (baseline 24.1±0.86 kg/m2); and 
21.5±0.64 kg/m2 in Group 3 (baseline 24.3±1.01 kg/m2).On Day 224, the BMI returned to 
baseline and was 23.7±0.62 kg/m2 in Group 1, 23.7±0.58 kg/m2 in Group 2, and 24.5±0.60 
kg/m2 in Group 3. 
The body mass increased in all three study groups, but in patients on Modulen this was 
accountable to increase of muscle and fat mass, and not to increase of total fluid content.This 
suggests that administration of Modulen improves the nutritional status profile. 
Assessment of NT-proBNP, adiponectin, leptin, CRP, IL-6, TNF-ǂ during administration of 
Modulen and Peptamen added to standard-of-care therapy in CHF patients with NYHA 
class III-IV. 
The level of NT-proBNP in all groups was over 3000 pg/mL. 
Reduction of chronic inflammation intensity was demonstrated in patients receiving 
Modulen:on Day 224, there was a decrease in levels of CRP (4.7±0.4 mg/ml vs. baseline 
8.9±0.7 mg/mL), IL-6 (5.2±0.4 U/L vs. baseline 11.8±0.8 U/L), TNF-ǂ (3.4±0.2 U/L vs. 
baseline 6.8±0.4 U/L).Levels of adiponectin also declined in patients on Modulen: 15.8±1.5 
µg/mL vs. baseline 24.4±1.5 µg/mL. No significant changes were demonstrated in Group 2 
and Group 3. 
There were no significant changes of leptin levels in any of the groups. 
Assessment of hospitalization events showed the following results.In Group 1, during 
treatment with Modulen, 32 hospitalization events were reported per year: 22 
hospitalizations were due to CHF decompensations, in 12 of these cases congestive 
pneumonia was also present; 2 events were due to myocardial infarctions; 5 events were for 
hypertensive crisis, with 2 of them progressing to CVA; 3 events were due to fibrillation 
paroxysms. Per-patient hospitalization rate was 0.55±0.01 event/person.There were 5 deaths 
over one year of observation in Group 1:2 deaths were caused by CHF decompensation, 2 
deaths were caused by CVA, 1 death was caused by AMI. 
In Group 1, during treatment with Peptamen, 38 hospitalization events were reported over 
one year of observation:of these, 27 hospitalization events were due to CHF 
decompensations, with 15 cases accompanied by congestive pneumonia; 3 events were due 
to acute myocardial infarctions; 7 events were due to hypertensive crisis, 1 of them 
progressed to CVA; 4 events were due to fibrillation paroxysms. Per-patient hospitalization 
rate was 0.95±0.02 event/person.There were 8 deaths over one year of observation in Group 
2:5 deaths were caused by CHF decompensation, 2 deaths were caused by AMI, 1 death was 
caused by CVA. 
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In Group 3, 48 hospitalizations were reported over one year of observation: 41 events were 
due to CHF decompensations, in 22 of which congestive pneumonia was also present; 2 
events were due to acute myocardial infarctions; 4 events were for hypertensive crisis, with 
2 cases progressing to CVA; 1 event was due to a fibrillation paroxysm.Per-patient 
hospitalization rate was 1.2±0.03 event/person.There were 12 deaths over one year of 
observation in Group 3:8 deaths were caused by CHF decompensation, 2 deaths were 
caused by AMI, 2 deaths were caused by CVA. 
4. Conclusion 
Rates of hospitalization events and deaths over one year were lower in subjects receiving 
Modulen compared to Peptamen and standard-of-care therapy. 
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